Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT)

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The fifteenth stock that takes place on our list is 4D Molecular Therapeutics, Inc. TheFly reported on January 27 that Barclays initiated coverage of FDMT with an Overweight rating and a $33 price target. Positive considerations for FDMT and the group in 2026 included the biotech industry’s solid fundamentals, the undervaluation of several companies, anticipated tailwinds from mergers and acquisitions, and a decreased emphasis ...